Skip to content
2-Day Shipping*
Secure Online Rx
Personalized Treatments
8,750+ Patients
Discreet Shipping
Compounded in the USA
No Surprises, Upfront Pricing
24/7 Support Team
Customized to Your Needs
Same-Day Doctor Visits & Rx
FSA & HSA Eligible
100% Entirely Online
Pay with Klarna
Ver en Español
Guide

Insulin resistance and GLP-1 medications, explained

What insulin resistance is, how it is found, how it links to prediabetes and weight, and what the FDA labels say GLP-1 medications do to insulin.

What insulin resistance is

Insulin is a hormone made by your pancreas. It helps glucose from food move into your cells to be used for energy. NIDDK explains that insulin resistance means the cells in your muscles, fat and liver do not respond to insulin the way they should. Over time your pancreas may not keep up, and glucose builds up in the blood. When blood glucose is higher than normal but not high enough to be type 2 diabetes, that is prediabetes. NIDDK reports that about 97.6 million adults in the United States had prediabetes in 2021.

Insulin resistance can lead to higher blood glucose and weight gain, which is why it comes up so often in conversations about weight.

Who is more likely to have it

NIDDK lists these risk factors: overweight, obesity or a large waist size; age 35 or older; a family history of diabetes; not being physically active; smoking; a history of gestational diabetes; certain ethnic backgrounds; conditions such as polycystic ovary syndrome (PCOS) and sleep apnea; and long term use of some medicines, such as glucocorticoids. Some of these you cannot change. Others, such as weight, activity and smoking, you can work on.

How it is found

Most people with insulin resistance or prediabetes have no symptoms. NIDDK says health care professionals may not test for insulin resistance itself, because that test is mainly used in research. Instead they test for prediabetes with blood tests:

  • A1C, which reflects your average blood glucose over about 3 months. Prediabetes is 5.7% to 6.4%.
  • Fasting plasma glucose. Prediabetes is 100 to 125 mg/dL.
  • Oral glucose tolerance test. Prediabetes is 140 to 199 mg/dL.

Your provider may also check cholesterol and triglycerides, since those can rise with insulin resistance.

What GLP-1 medications do to insulin

The FDA labels describe what these medications do in the body. The Mounjaro® (tirzepatide) label says tirzepatide enhances insulin release and lowers glucagon, a hormone that raises blood sugar, both depending on how high blood glucose is. It also says tirzepatide increases insulin sensitivity, as shown in a clamp study after 28 weeks of treatment in people with type 2 diabetes.

These medications are not FDA approved to treat insulin resistance or prediabetes on their own. Mounjaro® is approved to improve blood sugar control in type 2 diabetes. Zepbound® (tirzepatide) and Wegovy® (semaglutide) are approved, with a reduced calorie diet and more physical activity, for weight reduction in adults with obesity, or with overweight and at least one weight related health condition. Prediabetes can be one of those conditions, and your provider decides whether treatment fits.

This pertains to the brand name only. You cannot compare the personalized compounded version to this study because it is a different product entirely. For personalized compounds, the medical provider should be consulted.

Low blood sugar: when it is a risk

Because these medications lower blood glucose, the labels warn about hypoglycemia, or low blood sugar. The Zepbound® label reports that in a trial of people with type 2 diabetes, low blood sugar happened in 4.2% of people on Zepbound® and 1.3% on placebo, and the risk was higher in people also taking a sulfonylurea, a type of diabetes pill. The labels say the risk also goes up with insulin.

This pertains to the brand name only. You cannot compare the personalized compounded version to this study because it is a different product entirely. For personalized compounds, the medical provider should be consulted.

If you take any medicine for blood sugar, tell your provider before starting, so they can decide whether anything needs to change. Do not change a diabetes medicine on your own.

Lifestyle still does the heavy lifting

NIDDK says healthy living may help prevent or reverse insulin resistance and prediabetes: healthy food and drinks, regular physical activity, managing your weight and getting enough sleep. In the NIH funded Diabetes Prevention Program, losing 5% to 7% of starting weight helped people at high risk lower their chance of developing type 2 diabetes. NIDDK suggests starting with small changes and asking for support. Medication, when prescribed, works alongside these habits.

This pertains to the brand name only. You cannot compare the personalized compounded version to this study because it is a different product entirely. For personalized compounds, the medical provider should be consulted.

What this means for a compounded prescription

The label findings above come from studies of Mounjaro®, Zepbound® and Wegovy®, and personalized compounded semaglutide and tirzepatide are not FDA-approved and were not studied in those trials.

Personalized compounded medications differ from commercially available brand-name products in formulation, concentration, excipients, preparation methods, and other characteristics. Accordingly, clinical data from studies involving brand-name products should not be assumed to apply to personalized compounded formulations.

At this time, the studies referenced above have not evaluated the specific personalized compounded formulations being provided. Therefore, no claims of equivalence in safety, efficacy, quality, or clinical outcomes should be inferred from these studies.

Share any recent A1C or glucose results and every medicine you take with your provider. Dosing, stopping and switching are always your provider’s decision.

Questions

Frequently asked questions

Short answers to the questions people ask most about this topic.

NIDDK says healthy living, including healthy eating, regular activity, weight management and enough sleep, may help prevent or reverse insulin resistance and prediabetes. Your provider can tell you which steps matter most for you. Personalized compounded medications differ from commercially available brand-name products in formulation, concentration, excipients, preparation methods, and other characteristics. Accordingly, clinical data from studies involving brand-name products should not be assumed to apply to personalized compounded formulations. At this time, the studies referenced above have not evaluated the specific personalized compounded formulations being provided. Therefore, no claims of equivalence in safety, efficacy, quality, or clinical outcomes should be inferred from these studies.

NIDDK says the test for insulin resistance itself is mainly used in research. Providers usually check for prediabetes instead, with an A1C, a fasting glucose or an oral glucose tolerance test. Personalized compounded medications differ from commercially available brand-name products in formulation, concentration, excipients, preparation methods, and other characteristics. Accordingly, clinical data from studies involving brand-name products should not be assumed to apply to personalized compounded formulations. At this time, the studies referenced above have not evaluated the specific personalized compounded formulations being provided. Therefore, no claims of equivalence in safety, efficacy, quality, or clinical outcomes should be inferred from these studies.

The Mounjaro® label says tirzepatide increased insulin sensitivity in a clamp study after 28 weeks in people with type 2 diabetes. That is one study group, not a promise for any one person. This pertains to the brand name only. You cannot compare the personalized compounded version to this study because it is a different product entirely. For personalized compounds, the medical provider should be consulted. Personalized compounded medications differ from commercially available brand-name products in formulation, concentration, excipients, preparation methods, and other characteristics. Accordingly, clinical data from studies involving brand-name products should not be assumed to apply to personalized compounded formulations. At this time, the studies referenced above have not evaluated the specific personalized compounded formulations being provided. Therefore, no claims of equivalence in safety, efficacy, quality, or clinical outcomes should be inferred from these studies.

Wegovy® and Zepbound® are approved for weight reduction in adults with obesity, or with overweight and at least one weight related health condition, whether or not they have diabetes. Whether treatment fits you is your provider's decision. Personalized compounded medications differ from commercially available brand-name products in formulation, concentration, excipients, preparation methods, and other characteristics. Accordingly, clinical data from studies involving brand-name products should not be assumed to apply to personalized compounded formulations. At this time, the studies referenced above have not evaluated the specific personalized compounded formulations being provided. Therefore, no claims of equivalence in safety, efficacy, quality, or clinical outcomes should be inferred from these studies.

The labels say low blood sugar is more likely when these medications are taken with insulin or a sulfonylurea. If you take any blood sugar medicine, tell your provider before you start, and learn the signs of low blood sugar. Personalized compounded medications differ from commercially available brand-name products in formulation, concentration, excipients, preparation methods, and other characteristics. Accordingly, clinical data from studies involving brand-name products should not be assumed to apply to personalized compounded formulations. At this time, the studies referenced above have not evaluated the specific personalized compounded formulations being provided. Therefore, no claims of equivalence in safety, efficacy, quality, or clinical outcomes should be inferred from these studies.

Sources

  1. NIDDK, Insulin Resistance and Prediabetes, checked November 2026.
  2. Mounjaro® (tirzepatide) prescribing information, sections 1 and 12.2, DailyMed, Revised 8/2026, checked November 2026.
  3. Zepbound® (tirzepatide) prescribing information, sections 1, 5.7 and 7.1, DailyMed, Revised 8/2026, checked November 2026.
  4. Wegovy® (semaglutide) prescribing information, sections 1, 5.4 and 7.1, DailyMed, Revised 6/2026, checked November 2026.

Related

Important information about compounded medications

Personalized compounded semaglutide and personalized compounded tirzepatide are not FDA-approved and are not equivalent to FDA-approved products.

The FDA does not review compounded drugs for safety, effectiveness, or quality before they are marketed.

Compounding pharmacies are regulated by state boards of pharmacy for sterile compounding and are required to follow United States Pharmacopeia standards.

Treatment is not guaranteed. A licensed healthcare provider determines whether treatment is appropriate for each individual patient. Individual experiences and outcomes vary. If a patient is not qualified, a refund will be issued.

Bodi Envi is not a medical practice, pharmacy, or medication manufacturer. Brand names are trademarks of their respective owners.

Ready when you are

Start with an online assessment.

Answer a few questions about your health and goals. A licensed provider reviews your answers and decides whether treatment is appropriate for you.